Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2835219 vs erlotinib in KRAS-mutant stage IV NSCLC after platinum therapy
CTR20160156Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abemaciclib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jun 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20160156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160156.